Showing results (491-500 of 554) with videos related to

Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 StudyEmmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.
JCO Precision Oncology|February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumMaria I Carlo, Veda N Giri, Channing J Paller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2025
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic SubtypesJustin Hwang, Pornlada Likasitwatanakul, Sachin Kumar Deshmukh, et al.
Cancer Research Communications|May 6, 2024
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human MalignanciesCarly D Miller, John R Lozada, Nicholas A Zorko, et al.
Clinical Genitourinary Cancer|June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumChanning J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
JCO Precision Oncology|November 20, 2024
Analysis of Concordance Between Next-Generation Sequencing Assessment of Microsatellite Instability and Immunohistochemistry-Mismatch Repair From Solid TumorsRouba Ali-Fehmi, Harris Benjamin Krause, Robert T Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2017
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate CancerEmmanuel S Antonarakis, Scott T Tagawa, Giuseppe Galletti, et al.
Cancer Research|October 14, 2021
Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate CancerRajendra Kumar, Janet Mendonca, Olutosin Owoyemi, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
Cancer Immunology Research|November 15, 2024
A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate CancerShee Kwan Phung, Nicholas A Zorko, Yvette Soignier, et al.
Pageof 56